Baxter’s Heparin Ingredients Supplied By Unlicensed Chinese Company
This article was originally published in PharmAsia News
The active pharmaceutical ingredient in Baxter Internationals' blood thinner Heparin (heparin sodium) came from a factory in Changzhou, China, that had not been certified by China's State FDA. As a result, neither Chinese nor U.S. authorities had inspected the Changzhou Scientific Protein Laboratories plant where the API was made from pig intestines. The cause of four deaths and complications reported by 350 patients has not been determined. A Baxter spokeswoman said her company had inspected the plant on its own volition less than six months ago, but the U.S. supplier acknowledged the Changzhou plant had not been licensed by the SFDA. Scientific Protein did say the raw materials used had come from a licensed plant. (Click here for more
You may also be interested in...
SHANGHAI - China's State FDA has never inspected an API manufacturer that may be linked to a safety scare over Baxter Healthcare's injectable heparin, officials confirmed to PharmAsia News
Abbott reported third-quarter 2020 global sales of $8.9bn, driven by its strong position in COVID-19 tests. See what Abbott’s CEO Robert Ford said about it here.
With the threat of potentially hefty fines, China's newly passed Biosecurity Law will fundamentally change how the life science sector handles human genetic resources over years to come, legal experts say.